Company news

H. Lundbeck A/S news in 2025

H. Lundbeck A/S's news releases, calls and decks from 2025, newest first.

View company

Lundbeck receives orphan drug designation in the US and EU for Lu AG13909 for the treatment of patients with congenital adrenal hyperplasia

June 24, 2025

New data from phase III trial confirms efficacy of Vyepti® (eptinezumab) in Asian population with chronic migraine

June 21, 2025

Calls in 2025

Decks in 2025